A Look at the Year That Was in Biotech

FromThe Bio Report

Start listening View podcast show

A Look at the Year That Was in Biotech

FromThe Bio Report

ratings:

Length:

15 minutes

Released:

Dec 24, 2014

Format:

Podcast episode

Description

The year 2014 was one for the record books for the biotech industry. In part one of a two-part podcast, we take a look back at the year that was with Adam Feuerstein, senior columnist for TheStreet.com. Feuerstein discusses the growing controversy over drug pricing, the newsmakers of 2014, and lessons from the Dendreon bankruptcy.

Released:

Dec 24, 2014

Format:

Podcast episode

Titles in the series (100)

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

Skip carousel

The Forces Bringing Disruptive Change to Healthcare: Scientific breakthroughs, innovations in technology, and the changing use of data are among the forces that are driving disruptive changes to healthcare. A new report from the IMS Institute for Healthcare Informatics highlights a number of these deve... by The Bio Report
21 min listen
How New Funding Models Are Accelerating Drug Development: News last month of the Cystic Fibrosis Foundation’s $3.3 billion sale of royalty rights to Kalydeco and other Vertex Pharmaceuticals drugs it helped fund served as a bold statement to the growing prominence and power of venture philanthropy. We spok... by The Bio Report
18 min listen
Enlisting Monoclonal Antibodies to Combat Bacterial Resistance: There’s growing global concern about threat from antibiotic resistant pathogens. That’s leading to new interest in looking beyond traditional antibiotics to monoclonal antibodies to address the problem. We spoke to Ken Stover, senior director of infe... by The Bio Report
21 min listen
The Year in Biotech So Far and What’s Ahead: The biotech sector surged in the first half of the year despite volatile markets. M&A and financing continued to be robust as EvaluatePharma weighed in with its Pharma & Biotech Half-Year Report. We spoke to Jonathan Gardner, deputy news editor of EP... by The Bio Report
22 min listen
Epirus Sees Opportunities for Biosimilars Outside U.S.: The regulatory pathway for biosimilars is still a work in progress at the U.S. Food and Drug Administration, but around the world the industry is growing as regulators have resolved issues that remain obstacles in the United States. We spoke to Amit ... by The Bio Report
18 min listen
What’s Driving the Booming Market for Orphan Drugs: The market for Orphan drugs is growing at more than twice the rate of other prescription medicines In 2013, a record 260 therapeutics won orphan designations in the United States alone as science, policy, and pricing are fueling the trend for drugmak... by The Bio Report
18 min listen
The Lean Startup Takes Hold in the Life Sciences: The National Science Foundation and the National Institutes of Health, concerned about seeing the science they fund commercialized, have embraced the Lean Startup method as a way to improve the odds of success for new companies. Steve Blank, whose wo... by The Bio Report
23 min listen
Home-Brew Morphine, Dual Use Technology, and the Biologist’s Repsonsibilities: A recent article in Nature Chemical Biology that shows it is possible to convert sugar into morphine with genetically engineered yeast has sparked public attention over the potential illicit use of the technology and the need for regulation. The work... by The Bio Report
20 min listen
Reengineering Drug Discovery and Development: Drugmakers have employed new technologies to reduce the cost and time and it takes develop drugs and produce therapies that more precisely target the underlying biology driving diseases. Boston-based Berg Pharma is using artificial intelligence with ... by The Bio Report
21 min listen
Using Human Biology to Improve R&D: One problem with drug discovery and development is that answers about the way substances act in the human body are often not apparent early in the process. Though human cell assays have been used, they have their limitations. BioSeek’s BioMap technol... by The Bio Report
28 min listen
Will Increased FDA Regulation of Diagnostics Speed or Slow Development of Personalized Medicine: The U.S. Food and Drug Administration is moving to expand its regulatory domain by adding oversight of certain diagnostics it does not regulate today. The agency says thousands of these test are used daily to guide treatment decisions and diagnose di... by The Bio Report
27 min listen
Why Interoperability Is Much More than a Technology Problem: A new government report finds that healthcare providers in the United States are increasing their adoption of health information technology, but their willingness to do so is tied to the incentives available. What’s more, the government is implementi... by The Bio Report
26 min listen
How One Foundation is Getting the Biggest Bang for Its R&D Bucks: As pressure on government and corporate research budgets grow, organizations like the Multiple Myeloma Research Foundation are playing an increasingly critical role in advancing and accelerating drug development. The foundation’s efforts, including i... by The Bio Report
28 min listen
Telemedicine Grows, but Reimbursement Remains an Obstacle: While many may think of telemedicine as an example of digital health technologies that will reshape the future landscape of medicine, a new survey from the law firm Foley & Lardner shows it is very much part of healthcare’s here and now. We spoke to ... by The Bio Report
22 min listen
International Collaboration Seeks to Drive Breakthroughs in Progressive MS: There has been dramatic progress in the understanding and treatment of relapsing remitting multiple sclerosis, a debilitating neurodegenerative disorder. But progressive MS, a more advanced form of the disease, has remained elusive. Now, a novel coll... by The Bio Report
24 min listen
A Look at the Year That Was in Biotech: The year 2014 was one for the record books for the biotech industry. In part one of a two-part podcast, we take a look back at the year that was with Adam Feuerstein, senior columnist for TheStreet.com. Feuerstein discusses the growing controversy ov... by The Bio Report
15 min listen
The Power of IBM’s Watson Is Coming to an App Near You: IBM’s Watson Group recently announced an investment in Pathway Genomics, part of a $100 million initiative by the computing giant to spur innovation in entrepreneurial companies that seek to leverage its cognitive computing platform Watson. Pathway G... by The Bio Report
18 min listen
Remembering Industry Pioneer Ron Cape by The Bio Report
27 min listen
Weighing Adverse Events to Get at a Drug’s Real Costs: Adverse events from drugs cost the U.S. healthcare system an estimated $25 billion in 2013, but data from adverse events reporting is generally not factored into payer and provider decisions about what drugs are most cost-effective. The healthcare an... by The Bio Report
17 min listen
Calculating the Cost of Drug Development and What it Means: The cost of drug development, a metric that underlies discussions ranging from investment in startups to drug pricing, is a matter of great interest and controversy within the pharmaceutical industry. The Tufts Center for the Study of Drug Developmen... by The Bio Report
20 min listen
TheStreet’s Adam Feuerstein Previews ASCO 2015: Wall Street’s attention will turn to Chicago as the annual meeting of the American Society of Clinical Oncology runs from May 29 to June 2. Some 5,000 abstracts became available mid-month and investors have been sifting through them to gain insights ... by The Bio Report
14 min listen
Understanding the Cost and Value of Cancer Therapies: The National Comprehensive Cancer Network in October will release a new tool designed to help doctors understand the value of different cancer therapies by taking into account the costs of treatments. The effort from the influential group follows sim... by The Bio Report
22 min listen
Why Patent Trolling Threatens Biopharma: The biopharmaceutical industry has long been considered immune to the threat of patent trolls, patent holders who seek to monetize the value of a patent through enforcement rather than productive use. But a paper by UC Hastings Robin Feldman and Harv... by The Bio Report
16 min listen
Brittany Maynard and the Debate over the Right to Die: Brittany Maynard, a 29-year-old woman with terminal brain cancer who chose to end her own life with a lethal dose of medication, sparked a renewed discussion of so-called death with dignity laws. Maynard had become visible on social and traditional m... by The Bio Report
23 min listen
Why Big Pharma Hasn’t Been Able to Fix Its Revenue Gap with M&A by The Bio Report
17 min listen
Reinventing Tech Transfer: Universities are moving away from a passive approach to technology transfer to engage with industry in new partnerships, put a greater emphasis on translational research, and nurturing technologies so they can give rise to new products and companies.... by The Bio Report
21 min listen
Thinking Narrowly About Antibiotics: With the mapping of the human microbiome, a new understanding is emerging of the complex relationship between the microorganisms that live in the human gut, skin, and elsewhere on the body, and the role they play both in disease and in maintaining he... by The Bio Report
24 min listen
What a Decade of Investment Tells Us about the Health of Biotech: A detailed view of funding of emerging therapeutic companies over the past ten years shows despite a rebound in venture financing, companies continue to struggle to find early-stage money. Nevertheless, the report shows the overall health of investme... by The Bio Report
14 min listen
How the Sugar Industry Influenced Research to Protect Its Interests: A newly discovered archive of documents reveal the sugar industry’s efforts to shape the national research agenda away from the effects of sugar on tooth decay and push for programs to focus on alternatives to reducing consumption. We spoke to Cristi... by The Bio Report
13 min listen
Innovative Drugs Drive Big Increase in U.S. Spending: In April, the IMS Institute released a new report that U.S. drug spending in 2014 rose 13.1 percent to $373.9 billion, the largest single year increase in spending since 2001. A number of factors drove the increase including the launch of innovative ... by The Bio Report
20 min listen

More Episodes from The Bio Report

Skip carousel

Overcoming Resistance in Cancer with Chemistry: Kinase inhibitors have given rise to an era of precision medicine for the treatment of cancer, but the ability of cancer cells to mutate enables tumors to develop resistance to existing therapies. Nuvalent is developing therapies that both target the... by The Bio Report
30 min listen
Teaching an Old Drug a New Trick to Prevent Lyme Disease: Each year, an estimated 400,000 people in the United States will be diagnosed with Lyme disease, a billion-dollar healthcare problem caused by a bacterial infection that is transmitted through the bite of a tick. The condition can cause joint pain an... by The Bio Report
20 min listen
A New Class of Cell Therapies to Target Solid Tumors: In February, the U.S. Food and Drug Administration approved the first tumor-infiltrating lymphocyte, or TIL therapy, for solid tumors. The approval was hailed as a milestone that points the path forward for a new class of cell therapies for solid tum... by The Bio Report
33 min listen
Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies: Lipids have long been used as drug delivery vehicles, but HighField Biopharmaceutics is repurposing lipids as drugs to fight cancer. The company’s technology platform is seeking to change the immunotherapy landscape with new treatments that are bette... by The Bio Report
35 min listen
A Company Born from a Father Who Wore His Heart on His Sleeve: Jeremiah Robison’s daughter Sofia was born with cerebral palsy, a congenital movement disorder. Watching her physicians use body monitors to measure her gait, and later apply functional electrical stimulation as physical therapy, gave him an idea to ... by The Bio Report
32 min listen
Using AI to Improve Burn Care: Physicians treating people with burns typically incorrectly assess the depth of burn wounds in about 25 to 30 percent of cases. That, in part, is due to a lack of diagnostic tools to assess the severity of a burn and to determine the best approach to... by The Bio Report
24 min listen
A Home for Biotech in the City that Never Sleeps: New York City is not the first place that comes to mind when thinking of biotech clusters, but the Big Apple has been a growing center of biomedical innovation with its mix of academic research hospitals, finance, and growing number of biopharmaceuti... by The Bio Report
33 min listen
Biopharma R&D Growing Stronger: Funding levels, drug launches, and R&D success rates all grew in 2023, according to a new report from the IQVIA Institute for Human Data Science. Global funding of biopharmaceutical research and development increased to $72 billion, up from $61 b... by The Bio Report
31 min listen
The Benefits of Having a Multitude of Cins: In January 2023, AstraZeneca agreed to acquire CinCor Pharma, the CinRx cardio-renal disease therapy subsidiary, for $1.3 billion. The deal included a potential additional $500 million milestone payment. The price represented a 121 percent premium to... by The Bio Report
33 min listen
Making ADCs Smarter and Safer with a Simple Twist of Fate: Antibody-drug conjugates can deliver chemotherapy directly to tumors but more than 95 percent of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity. Mythic Therapeutics FateControl technology improves the uptake of... by The Bio Report
24 min listen
Targeting a Natural Repair System to Restore Brain Health: The HGF/MET neurotrophic system plays a critical role in the maintenance and repair of connections in the brain. Enhanced signaling along this pathway has the potential to reduce inflammation, slow neurodegeneration, and provide neuroprotection. Athi... by The Bio Report
19 min listen
Programing Cells in a Predictable and Scalable Way: The advent of induced pluripotent stem cells, cells that can be coaxed into becoming virtually any type of cell within the body, promised to usher in a new era of regenerative medicine and improved drug discovery. In practice, though, the ability to ... by The Bio Report
32 min listen
Why DNA May Be the Data Storage Medium of the Future: Some 100 trillion gigabytes of data are created and consumed each year, an amount that is expected to double by 2025. The demand for data storage carries the need for significant physical space and power requirements in the form of digital data cente... by The Bio Report
32 min listen
Scouring Genetic Variation within Our Cells for Drug Targets: People tend to think of each person having their own unique genome. Quotient Therapeutics is taking an approach to drug discovery based on the reality that from cell to cell within a given individual, there can be trillions of divergent genomes. Chan... by The Bio Report
26 min listen
Correcting Gene Dysregulation to Treat Diseases: Regardless of the cause of a disease, most diseases involve gene dysregulation. Omega Therapeutics is developing a new class of programmable, epigenomic, mRNA medicines designed to make specific epigenetic changes and correct abnormal gene expression... by The Bio Report
45 min listen
Using Technology to Regain Abilities after Spinal Cord Injury: The effects of spinal cord injury extend beyond the loss of mobility. They can include a toll on mental health, a feeling of exclusion, and a general decline in the quality of life as a result of being able to stand and interact eye-to-eye with other... by The Bio Report
25 min listen
Why Drug Developers Have a Growing Interest in Targeting Mitochondria: Mitochondria are often referred to as the “powerhouses” of the cell, but as scientists gain a greater understanding of these essential organelles, they are coming to discover they play a more expansive role in health and disease. The Foundation for t... by The Bio Report
39 min listen
Beefing Up Computational Muscle to Understand Molecular Activity of Drug Candidates: Sandbox AQ, the Alphabet spin-out backed with $500 million in investment, in June 2023 unveiled it AQBioSim division. The division is working to bring SandoxAQ’s AI and quantum-inspired computing to develop new treatments for intractable medical cond... by The Bio Report
32 min listen
Targeting a Multitude of CIN in Cancer Cells: It’s long been understood that chromosomal instability (CIN) is a characteristic of cancer cells, but it also represents a key difference between cancer cells and healthy cells that can be exploited. Volastra is developing medicines for a wide range ... by The Bio Report
21 min listen
The Year in Biotech and What’s Ahead in 2024: Though the year began with a banking crisis and has been marked with layoffs and restructurings, we have managed to avoid a feared recession. It’s been a big year for new drug approvals, M&A activity has been brisk, and biotech stocks have rallie... by The Bio Report
33 min listen
Transforming Healthcare with Data: Vik Bajaj has long lived at the intersection of physical sciences, engineering, data science, and the life sciences—first as an academic working to improve diagnostic imaging at Stanford University and later as a chief scientific officer at GRAIL and... by The Bio Report
51 min listen
Realizing the Promise of IL-2 Therapies with AI: Interleukin-2 therapies have been seen as promising ways to treat solid tumors, but they have proven challenging because of the ability of IL-2 to both activate and suppress the immune system. Their effectiveness has been limited because of potential... by The Bio Report
23 min listen
Unlocking Real-World Data to Improve Outcomes: Real-world data promises to provide insights that lead to better therapies, change how we treat diseases, and improve outcomes for patients. One of the limits of realizing benefits from all of the health information we are swimming in is the lack of ... by The Bio Report
40 min listen
A Silicon Valley Entrepreneur Investing at the Intersection of Tech and Biotech: Artificial intelligence promises to reshape the healthcare landscape and deliver new insights into the molecular drivers of health and wellness, provide rapid diagnoses of patients, and discover and design therapies that extend beyond human imaginati... by The Bio Report
25 min listen
A Company Betting Its Physics-Based AI Will Fuel a Quantum Leap in Drug Discovery: Though many drug developers are harnessing AI to create novel chemical compounds, Iambic Therapeutic’s generative AI is leveraging quantum mechanics to get to better drugs. It says its physics-informed machine learning approach has yielded promising ... by The Bio Report
24 min listen
Detecting Alzheimer’s Disease Early through a Blood Test: One of the challenges with treating Alzheimer’s disease is diagnosing patients early enough in the course of its progression to have a meaningful impact with treatments. Sunbird Bio said it can accurately detect and differentiate specific proteins th... by The Bio Report
25 min listen
Addressing Supply-Chain Challenges Underlying Drug Shortages with Synthetic Biology: About 40 percent of all drugs in the Western world are derived from plants. But challenges with producing a reliable supply inherent with materials derived from agricultural processes can lead to drug shortages as climate events, pests, and plant dis... by The Bio Report
28 min listen
Building Better and More Affordable Vaccines: The COVID 19 pandemic provided a painful reminder of the global need to protect people against the threat of existing and emerging infectious diseases. Emergex Vaccines is developing fully synthetic vaccines that provide advantages over live attenuat... by The Bio Report
42 min listen
Overcoming Resistance to Targeted Therapies: The advent of targeted therapies has contributed to notable progress in the fight against cancer, but the ability of cancers to develop resistance to these precision medicines continues to leave patients in need of new approaches. Concarlo Therapeuti... by The Bio Report
30 min listen
Using Tumor Gene Therapy to Overcome Barriers to Immunotherapies: There have been significant advances to immunotherapies since their first introduction, but challenges remain to realizing their full potential in solid tumors. That’s because of the ability of tumors to use multiple mechanisms to evade the immune sy... by The Bio Report
30 min listen

Related podcast episodes

Skip carousel

Biotech in 2016 and the Year Ahead with TheStreet’s Adam Feuerstein: With 2016 drawing to a close and the biotech industry gearing up for the annual JPMorgan Healthcare Conference in San Francisco, we continued our holiday tradition of checking in with Adam Feuerstein, senior columnist for TheStreet. We spoke to Feuer... by The Bio Report
21 min listen
Episode 56 by Biotech Hangout
63 min listen
The ATMP and CDMO deal maker: In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Anderson, General Partner at Ampersand Capital Partners. Your host, Raman Sehgal, discusses the pharmaceutical and biotechn... by Molecule to Market: Inside the outsourcing space
54 min listen
Opioid MedMal and Litigation Risks: An Interview with Mr. Harry Nelson: Hosts Dr. Don Stader and Dr. Mary Andrawis, PharmD sit down to discuss the intricacies of litigation risks that come with prescribing opioids with healthcare attorney, Mr. Harry Nelson. Tune in to review the risks and practices you can adopt to... by Compass Opioid Stewardship Expert Spotlight
50 min listen
Ryan Hampton: Big Pharma, Bankruptcy and Injustice: Join us for Ryan Hampton’s inside account of Purdue Pharma’s role in the overdose crisis—and for a chilling exposé of those who circumvented justice. by Commonwealth Club of California Podcast
64 min listen
Episode 31: The Truth About Ivermectin with Dr. Pierre Kory by The Truth with Lisa Boothe
62 min listen
Ep. 1034: Gregory Zuckerman Interview with Michael Covel on Trend Following Radio: Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of... by Michael Covel's Trend Following
56 min listen
Inside the Race to the Coronavirus Vaccine with Brendan Borrell by Inquiring Minds
45 min listen
What's Next For COVID Vaccines With Tonix Pharmaceuticals' Seth Lederman, M.D. by Business Of Biotech
67 min listen
Howard Friedman, "Ultimate Price: The Value We Place on Life" (U California Press, 2020): What is the price of a life? by New Books in Public Policy
46 min listen
Howard Friedman, "Ultimate Price: The Value We Place on Life" (U California Press, 2020): What is the price of a life? by New Books in Economics
46 min listen
The Top Tech News Stories of 2012: Part 2: What were some of the big scientific discoveries of 2012? What were some of the big social media stories? What happened at RIM? Join Chris and Jonathan as they take a look back on the year in tech in the conclusion of this two-part episode. by TechStuff
38 min listen
13. Veterinary Forensic Files: Investigating & Prosecuting Animal Crimes by Fully Vetted
21 min listen
Pen and Sword: Data.World: In this episode of RANE's Pen and Sword podcast, host Fred Burton speaks to serial entrepreneur, Brett Hurt. Hurt's latest startup is data.world, a Public Benefit Corporation focused on data and analysis that also includes the world's largest collabo... by RANE Podcast Series
24 min listen
David Bronner of Dr. Bronner's - Cosmic Engagement, Psychedelics, and ALL-ONE! (#140): David Bronner is Cosmic Engagement Officer (CEO) of Dr. Bronner’s, the grandson of company founder, Emanuel Bronner, and a fifth-generation soap maker. He is a dedicated vegan and enjoys surfing and dancing late into the night. by Ten Laws with East Forest
59 min listen
DeSantis Slays Newsom; COVID Jabs Slay Humanity | Guest: Sonia Elijah | 12/1/23 by Conservative Review with Daniel Horowitz
65 min listen
Ep. 8 | 2021: A Year in Review: It's December and we've made it to the end of 2021. This was another year dominated by COVID-19 in the field of social protection - and we've certainly spent plenty of time talking about that on this show. But while we were preoccupied with the pandem... by Social Protection Podcast
36 min listen
Howard Friedman, "Ultimate Price: The Value We Place on Life" (U California Press, 2020): What is the price of a life? by New Books in Law
46 min listen
How Far Back Does the Pharma Rot Go? | Guest: Dr. Pierre Kory | 4/14/22 by Conservative Review with Daniel Horowitz
74 min listen
Pulling Together: When the COVID-19 Pandemic grew rapidly in early 2020, medical supplies were in short supply. Different areas and organizations struggled with different types of issues, and one of the higher profile issues was with ventilators. In March, the... by Voice of the DBA
3 min listen
How Liquid Is Trump? by The Powers That Be: Daily
18 min listen
116. Howard Steven Friedman — Ultimate Price: The Value We Place on Life: How much is a human life worth? Individuals, families, companies, and governments routinely place a price on human life. The calculations that underlie these price tags are often buried in technical language, yet they influence our economy, laws,... by The Michael Shermer Show
70 min listen
Pharma By The Numbers: Celebrating 20 Years of Xtalks with an Analysis of the Industry by Xtalks Life Science Podcast
56 min listen
Trailer by On the Contrary by IDR
3 min listen
Episode 17: Dr. Torsten Schröder - Founder & Chief Medical Officer of Perfood by First In Human By Vial
17 min listen
A Look at What’s Ahead for Biopharma in 2017: Investors bid up biopharmaceutical stocks following the election of Donald Trump as President of the United States. It reflected a belief that a Trump administration will remove the threat of price controls on drugs and bring about a friendlier regul... by The Bio Report
25 min listen
A year of pandemic and inequality by The Take
19 min listen
The world after the coronavirus pandemic with Fareed Zakaria: The coronavirus pandemic is more global, dramatic and unusual than any crisis we've seen in a long time, says journalist Fareed Zakaria. by The TED Interview
35 min listen
Coup Clutz Clan by Lovett or Leave It
79 min listen
S2 Ep6: S2 #6 The Public Good: Maximising Outcomes by The CERN Sparks! Podcast
26 min listen

Discover this podcast and so much more

A Look at the Year That Was in Biotech

A Look at the Year That Was in Biotech

Description

Titles in the series (100)

More Episodes from The Bio Report

Related podcast episodes